# KANDLELIT-001: HCP commentary report

> 52 verified statements (11 from clinicians verified by NPI or staff page) from 18 commentary sources · 6 findings · updated Oct 31, 2026

## Report

- Trial: A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors
- NCT ID: NCT05067283
- Registry: https://clinicaltrials.gov/study/NCT05067283
- Sponsor: Merck Sharp & Dohme LLC
- Phase: Phase 1
- Status: Recruiting
- Drugs tested: calderasib (MK-1084); calderasib (MK-1084) plus pembrolizumab; calderasib (MK-1084) plus cetuximab
- Indication: KRAS G12C-mutant advanced solid tumors
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: 4a6b74948b1393307240e451d8da1986a38cc35156807905f0484bf30c22e078

## Counts

- HCP commentary sources screened: 59
- Sources cited by verified statements: 18
- Verified statements: 52
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 11
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 12
- Voices cited: 12
- Cited voices identity-verified: 9
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

KANDLELIT-001 asks whether calderasib, alone or in combinations, can provide tolerable treatment and antitumor activity in advanced KRAS G12C-mutated cancers. Commentary comes from X and LinkedIn posts and YouTube interviews; clinical roles are not established for every contributor. Discussion turns on what randomized evidence and hepatic safety would support frontline calderasib–pembrolizumab, whether chemotherapy adds value in colorectal cancer combinations, and how response frequency relates to durability with calderasib monotherapy in previously treated NSCLC.

## Open Medical Affairs question

Which mature, randomized and regimen-specific efficacy and safety findings would resolve the expressed uncertainty without turning exploratory signals into treatment recommendations?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Frontline NSCLC enthusiasm remains conditional on randomized evidence and hepatic safety
- F2. CRC doublet enthusiasm does not extend unqualified to the chemotherapy triplet
- F3. Participation messaging pairs active-treatment access with an unverified approval premise
- F4. Previously treated NSCLC: modest response frequency and durability are separate judgments
- F5. The presenter expresses emphatic, tumor-specific enthusiasm outside NSCLC and CRC
- F6. Combination-era optimism sits alongside speculative competitive positioning

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 13 | 7 | 5 | 3 | none recorded | 3 |
| F2 | 12 | 6 | 6 | 5 | none recorded | 3 |
| F3 | 5 | 2 | 1 | 0 | none recorded | 3 |
| F4 | 7 | 5 | 3 | 1 | none recorded | 2 |
| F5 | 14 | 4 | 4 | 2 | none recorded | 3 |
| F6 | 4 | 4 | 2 | 3 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 10 | 0 | 0 | 0 | 3 | 13 | 2 | 3 posts and articles, 2 podcasts and video | yes |
| F2 | 1 | 3 | 0 | 1 | 7 | 15 | 1 | 6 posts and articles | yes |
| F3 | 2 | 0 | 0 | 0 | 3 | 6 | 0 | 1 podcast or video | yes |
| F4 | 4 | 0 | 0 | 0 | 3 | 7 | 2 | 1 post or article, 2 podcasts and video | yes |
| F5 | 9 | 0 | 0 | 0 | 5 | 14 | 8 | 2 posts and articles, 2 podcasts and video | yes |
| F6 | 3 | 0 | 0 | 1 | 0 | 4 | 1 | 2 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT): no finding draws on it directly
- Primary endpoint: Number of Participants Who Experience an Adverse Event (AE): F1 (2 shared claims), F2 (2 shared claims), F4 (1 shared claims), F5 (2 shared claims)
- Primary endpoint: Number of Participants Who Discontinue Study Treatment Due to an AE: F2 (1 shared claims), F5 (2 shared claims)
- Secondary endpoints: F1 (6 shared claims), F2 (4 shared claims), F4 (3 shared claims), F5 (6 shared claims)
- Population and setting: F1 (1 shared claims), F3 (2 shared claims), F4 (1 shared claims), F5 (2 shared claims)
- The comparison: F1 (1 shared claims), F2 (7 shared claims), F3 (2 shared claims), F4 (1 shared claims)
- Safety and tolerability: F1 (3 shared claims), F2 (4 shared claims), F4 (1 shared claims), F5 (3 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (2 shared claims), F5 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. Frontline NSCLC enthusiasm remains conditional on randomized evidence and hepatic safety

An X post addresses what evidence would inform treatment decisions about first-line calderasib plus pembrolizumab in KRAS G12C-mutated NSCLC.

Source: X thread, 2026-10-25.

### F2. CRC doublet enthusiasm does not extend unqualified to the chemotherapy triplet

An X thread addresses what adding chemotherapy contributes to MK-1084 plus cetuximab in advanced colorectal cancer.

Source: X thread, 2025-05-23.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 52 | Paid |
| Trial aspects mapped | 13 | Free |
| Sources with links | 18 | Counts free |
| Speaker attribution for cited voices | 12 | Paid |

## Trial aspects

12 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) | no commentary found | 0 | 0 |
| Primary endpoint: Number of Participants Who Experience an Adverse Event (AE) | discussed | 6 | 6 |
| Primary endpoint: Number of Participants Who Discontinue Study Treatment Due to an AE | discussed | 3 | 3 |
| Secondary endpoints | discussed | 18 | 9 |
| Population and setting | discussed | 5 | 4 |
| The comparison | discussed | 10 | 5 |
| Safety and tolerability | discussed | 10 | 9 |
| Design and conduct | discussed | 7 | 7 |
| Evidence needed before frontline NSCLC practice change | discussed | 10 | 4 |
| Previously treated NSCLC: response frequency versus durability | discussed | 2 | 2 |
| Tumor-specific enthusiasm outside NSCLC and colorectal cancer | discussed | 10 | 4 |
| Active-treatment access and approval-based reassurance | discussed | 3 | 1 |
| Combination-era expectations and wider anti-KRAS G12C competition | discussed | 4 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 42 | 10 |
| YouTube | 6 | 5 |
| Bluesky threads | 8 | 1 |
| LinkedIn posts | 3 | 2 |

- Screened window: 2023-09-15 to 2026-10-25
- Cited window: 2023-09-15 to 2026-10-25
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors
- Registry: NCT05067283 (https://clinicaltrials.gov/study/NCT05067283)
- Study IDs: 1084-001 · MK-1084-001 (MSD) · jRCT2041220034 (jRCT) · 2022-501563-40-00 (EU CT) · U1111-1281-2482 (UTN)
- Sponsor: Merck Sharp & Dohme LLC
- Design: Phase 1 · interventional, non randomized, parallel, phase1
- Status: Recruiting
- Enrollment: 830 (estimated)
- Start: 2021-12-17 (actual)
- Primary completion: 2030-02-25 (estimated)
- Primary endpoint: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) (Up to ~21 days)
- Primary endpoint: Number of Participants Who Experience an Adverse Event (AE) (Up to ~56 months)
- Primary endpoint: Number of Participants Who Discontinue Study Treatment Due to an AE (Up to ~56 months)
- Intervention: Calderasib (drug)
- Intervention: Pembrolizumab (biological)
- Intervention: carboplatin (drug)
- Intervention: pemetrexed (drug)
- Intervention: cetuximab (biological)
- Intervention: oxaliplatin (drug)
- Intervention: leucovorin (drug)
- Intervention: 5-fluorouracil (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 45 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- Repeated posts, institutional presentation coverage, reshares and closely matching interview versions are not independent HCP assessments.
- The reported cohort results differ in population, prior treatment, biomarker group, regimen and presentation. Common analysis dates are not established, and the figures cannot support a simple cross-cohort efficacy ranking.
- CRC triplet safety is reported differently: 25% grade ≥3 treatment-related adverse events in a speaker's account versus 15% grade 3+ adverse events in another speaker's. The event definitions and numerical difference remain unresolved.
- No full protocol or results publication is available in the material reviewed. Regulatory information is incomplete and does not establish the trial-information video's assertion that all constituent drugs are approved.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Post and video publication dates are not necessarily presentation dates. Differences between reports do not establish a change of mind or disagreement across settings.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (52 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (9 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/kandlelit-001-nct05067283
- Agents: POST https://www.erudio.com/api/orders with {"report": "kandlelit-001-nct05067283", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=kandlelit-001-05067283

## Cite

Erudio Health. KANDLELIT-001 (NCT05067283): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/kandlelit-001-nct05067283

## Machine access

- JSON: https://www.erudio.com/reports/kandlelit-001-nct05067283.json
- Markdown: https://www.erudio.com/reports/kandlelit-001-nct05067283.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "kandlelit-001-05067283"}`